Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy

References

• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–862.
   PubMed Web of Science ®Google Scholar
• Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:323–329.
   PubMed Web of Science ®Google Scholar
• Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53:209–215.
   PubMed Web of Science ®Google Scholar
• Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35:1786–1794.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607.
   PubMed Web of Science ®Google Scholar
• Castellino RA, Blank N, Hoppe RT, et al. Hodgkin disease: contributions of chest CT in the initial staging evaluation. Radiology. 1986;160:603–605.
   PubMed Web of Science ®Google Scholar
• Crowe JE. Cardiophrenic adenopathy in Hodgkin disease. Am J Dis Child. 1975;129:116–117.
   PubMedGoogle Scholar
• Meyer JE, McLoud TC, Lindfors KK. CT demonstration of cardiophrenic angle lymphadenopathy in Hodgkin disease. J Comput Assist Tomogr.1985;9:485–488.
   PubMed Web of Science ®Google Scholar
• Cho CS, Blank N, Castellino RA. CT evaluation of cardiophrenic angle lymph nodes in patients with malignant lymphoma. AJR Am J Roentgenol. 1984;143:719–721.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058.
   PubMed Web of Science ®Google Scholar
• Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.
   PubMed Web of Science ®Google Scholar
• Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–18.
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
   PubMed Web of Science ®Google Scholar
• Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308–1315.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63:214–223.
   PubMed Web of Science ®Google Scholar
• Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:175–182.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374:2419–2429.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22:2835–2841.
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–4206.
   PubMed Web of Science ®Google Scholar
• Aronberg DJ, Peterson RR, Glazer HS, et al. Superior diaphragmatic lymph nodes: CT assessment. J Comput Assist Tomogr. 1986;10:937–941.
   PubMed Web of Science ®Google Scholar
• Dorfman RE, Alpern MB, Gross BH, et al. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991;180:319–322.
   PubMed Web of Science ®Google Scholar
• Sussman SK, Halvorsen RA Jr, Silverman PM, et al. Paracardiac adenopathy: CT evaluation. Am J Roentgenol. 1987;149:29–34.
   PubMed Web of Science ®Google Scholar
• Farmakis S, Vejdani K, Muzaffar R, et al. Detection of metastatic disease in cardiophrenic lymph nodes: FDG PET/CT versus contrast-enhanced CT and implications for staging and treatment of disease. Front Oncol. 2013;3:260.
   PubMedGoogle Scholar
• Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol. 2006;78:1–5.
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21:3601–3608.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26:5170–5174.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Hoppe RT. Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:40–45.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235–243.
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Marzo K, Balzarotti M, Rodari M, et al. Dimension of residual CT scan mass in Hodgkin’s lymphoma (HL) is a negative prognostic factor in patients with PET negative after chemo+/− radiotherapy. Blood. 2011;118:93.
   Web of Science ®Google Scholar
• Torok JA, Wu Y, Prosnitz LR, et al. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92:54–59.
   PubMed Web of Science ®Google Scholar
• Figura N, Flampouri S, Mendenhall NP, et al. Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. Adv Radiat Oncol. 2017;2:197–203.
   PubMedGoogle Scholar